Contrast developer Nycomed Amersham Imaging has signed an agreement with Canadian pharmaceutical firm Neurochem that could result in new products for detecting early signs of Alzheimer's disease.
Under the collaboration, Neurochem will review its library of clinical therapeutic compounds and identify molecules that bind to beta-amyloid, a key marker for Alzheimer's disease. Nycomed Amersham will then synthesize radiolabeled binding molecules to be used to detect Alzheimer's with diagnostic imaging tools.
The goal is to enable the early identification of amyloid plaques in the brains of Alzheimer's patients, before symptoms of the disease are observed.
By AuntMinnie.com staff writersJuly 19, 2001
Related Reading
Wagner taps PET Alzheimer’s study as SNM 2001’s Image of the Year, June 26, 2001
PET, SPECT differ in Alzheimer's imaging, June 25, 2001
FDA approves Nycomed Amersham's EchoSeed, June 4, 2001
Nycomed, HSCA extend contract, May 31, 2001
Nycomed Amersham changes name to Amersham PLC, May 11, 2001
Nycomed gets sole-source TheraSeed deal from Premier, May 9, 2001
Copyright © 2001 AuntMinnie.com
